Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis

Area of Science:

• Neuroimmunology
• Molecular Biology
• Pharmacogenomics

Background:

• Interferon beta (IFNB) is a standard therapy for multiple sclerosis (MS), but its precise molecular mechanisms remain unclear.
• Long-term IFNB treatment necessitates reliable early biomarkers to track therapeutic activity, yet longitudinal transcriptional studies are scarce.

Purpose of the Study:

• To identify consistent and early transcriptional biomarkers of interferon beta (IFNB) activity in multiple sclerosis (MS) patients undergoing long-term therapy.
• To evaluate the temporal expression patterns of potential biomarkers over one year of IFNB treatment.

Main Methods:

• Microarray analysis was performed on blood samples from 18 MS patients treated with IFNB1b.
• Gene expression was monitored at four time points over a one-year period.
• Analysis focused on genes exhibiting consistent and significant expression changes across the majority of patients.

Main Results:

• A significant overrepresentation of interferon-regulated genes was observed.
• Fifteen specific gene markers (e.g., EIF2AK2, IFI6, MX1, ISG15) demonstrated consistent, differential expression across all measured time points.
• These identified biomarkers showed early detection and sustained expression patterns throughout the study duration.

Conclusions:

• The fifteen identified genes represent robust, early, and long-lasting biomarkers for monitoring interferon beta (IFNB) activity in multiple sclerosis (MS) patients.
• These biomarkers offer a valuable tool for assessing treatment efficacy in long-term clinical management.
• Established biomarkers like Interleukin-8 and STAT1 exhibited less consistent or delayed expression patterns compared to the newly identified markers.